Tilray Brands, Inc. (TLRY) Quick Ratio
- Quick ratio · latest quarter: Value 1.17×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-05-31..
Quick ratio
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.17× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-05-31. $420.44M ÷ $358.38M ≈ 1.17× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 420.44M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 358.38M USD | Liabilities, Current |
| Cash and equivalents | 225.98M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 5.29M USD | Marketable Securities, Current |
| Customer receivables | 189.17M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 301.19M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | $420.44M | $358.38M | $225.98M | $5.29M | $189.17M | $301.19M | 1.17× |
| 2026-02-28 | $338.30M | $257.54M | $204.62M | $15.31M | $118.37M | $292.30M | 1.31× |
| 2025-12-31 | $377.85M | $280.30M | $221.67M | $34.70M | $121.49M | $270.88M | 1.35× |
| 2025-11-30 | $400.62M | $259.31M | $246.70M | $44.85M | $109.07M | $283.20M | 1.54× |
| 2025-08-31 | $371.90M | $267.63M | $264.83M | $0.00 | $107.08M | $282.79M | 1.39× |
| 2025-05-31 | $377.85M | $280.30M | $221.67M | $34.70M | $121.49M | $270.88M | 1.35× |
| 2024-12-31 | $351.78M | $262.17M | $199.96M | $48.46M | $103.37M | $263.40M | 1.34× |
| 2024-11-30 | $364.99M | $278.52M | $189.70M | $62.55M | $112.74M | $266.01M | 1.31× |
| 2024-08-31 | $384.09M | $293.55M | $205.19M | $74.87M | $104.04M | $264.30M | 1.31× |
| 2024-05-31 | $362.22M | $299.17M | $228.34M | $32.18M | $101.69M | $252.09M | 1.21× |
| 2024-02-29 | $315.40M | $329.10M | $146.25M | $79.61M | $89.54M | $244.14M | 0.96× |
| 2023-12-31 | $362.22M | $299.17M | $228.34M | $32.18M | $101.69M | $252.09M | 1.21× |
| 2023-11-30 | $350.39M | $394.99M | $143.37M | $116.42M | $90.60M | $252.70M | 0.89× |
| 2023-08-31 | $546.93M | $537.27M | $177.52M | $287.33M | $82.08M | $232.07M | 1.02× |
| 2023-05-31 | $534.76M | $432.98M | $206.63M | $241.90M | $86.23M | $200.55M | 1.24× |
| 2023-02-28 | $486.63M | $469.68M | $165.00M | $243.29M | $78.34M | $202.80M | 1.04× |
| 2022-11-30 | $523.21M | $426.50M | $190.22M | $243.29M | $89.70M | $240.95M | 1.23× |
| 2022-08-31 | (m) | $273.26M | $490.64M | (m) | $98.35M | $244.65M | (m) |
| 2022-05-31 | (m) | $280.34M | $415.91M | (m) | $95.28M | $245.53M | (m) |
| 2022-03-31 | $511.19M | $280.34M | $415.91M | $0.00 | $95.28M | $245.53M | 1.82× |
| 2022-02-28 | (m) | $282.43M | $279.21M | (m) | $89.89M | $273.29M | (m) |
| 2021-11-30 | (m) | $314.93M | $331.78M | (m) | $84.58M | $233.02M | (m) |
| 2021-08-31 | (m) | $526.83M | $376.30M | (m) | $97.18M | $251.51M | (m) |
| 2021-05-31 | (m) | $401.24M | $488.47M | (m) | $87.31M | $256.43M | (m) |
| 2021-03-31 | (m) | $283.99M | $416.37M | (m) | $28.30M | $96.54M | (m) |
| 2020-12-31 | (m) | $181.28M | $189.70M | (m) | $29.03M | $93.64M | (m) |
| 2020-09-30 | (m) | $133.53M | $155.21M | (m) | $24.80M | $89.92M | (m) |
| 2020-06-30 | (m) | $163.67M | $137.21M | (m) | $26.61M | $93.09M | (m) |
| 2020-05-31 | (m) | $119.89M | $360.65M | (m) | $37.93M | $139.78M | (m) |
| 2020-03-31 | (m) | $171.37M | $173.99M | (m) | $38.32M | $95.59M | (m) |
| 2019-12-31 | (m) | $92.43M | $96.79M | (m) | $36.20M | $87.86M | (m) |
| 2019-09-30 | (m) | $130.20M | $100.16M | (m) | $36.04M | $110.49M | (m) |
| 2019-06-30 | (m) | $175.91M | $184.55M | (m) | $24.61M | $75.32M | (m) |
| 2019-03-31 | (m) | $170.36M | $294.20M | (m) | $19.71M | $48.71M | (m) |
| 2018-12-31 | (m) | $25.94M | $487.25M | (m) | $16.52M | $16.21M | (m) |
| 2018-09-30 | (m) | $26.90M | $104.25M | (m) | $5.75M | $12.11M | (m) |
| 2018-06-30 | (m) | $62.85M | $25.33M | (m) | $1.76M | $6.75M | (m) |
| 2017-12-31 | (m) | $50.22M | $2.32M | (m) | $983.00K | $7.42M | (m) |
| 2017-06-30 | (m) | (m) | $7.32M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $7.53M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |